International Prices And Availability Of Pharmaceuticals In 2005

Danzon, Patricia M.; Furukawa, Michael F.
January 2008
Health Affairs;Jan/Feb2008, Vol. 27 Issue 1, p221
Academic Journal
This paper compares pharmaceutical spending, availability, use, and prices in twelve countries in 2005. Drug spending per capita was higher in the United States than in other countries. The United States had relatively high use of new drugs and high-strength formulations; other countries used more of older drugs and weaker formulations. Thus, whether U.S. overall volume of use is lower or higher depends on the measure of volume and type of product. Comprehensive price indexes show foreign prices to be 20-40 percent lower than U.S. manufacturer prices, but only 10-30 percent lower than U.S. public prices. Generics are cheaper in the United States than in other countries.


Related Articles

  • Generic substitution in Finland.  // WHO Drug Information;2004, Vol. 18 Issue 4, p269 

    Focuses on the aim of generic substitution at promoting cost-effective medical treatment in Finland. Requirement of the new practice to pharmacies to replace medical product prescribed by a doctor with a less expensive generic counterpart; Decision of the National Agency for Medicines on which...

  • Impact of an Annual Dollar Limit or "Cap" on Prescription Drug Benefits for Medicare Patients. Tseng, Chien-Wen; Brook, Robert; Keeler, Emmett; Mangione, Carol // JAMA: Journal of the American Medical Association;7/9/2003, Vol. 290 Issue 2, p222 

    Discusses the impact of an annual dollar limit or cap on prescription drug benefits for Medicare patients. Prescription benefit caps in the plan; Increase in the cost of prescription drugs since the enactment of Medicare; Lack of generic drug options; Out-of-pocket prescription costs.

  • BMI Research: Serbia & Montenegro Defence & Security Report: Serbia -- Pharmaceuticals.  // Serbia & Montenegro Defence & Security Report;Q1 2009, p71 

    BMI calculates that the value of pharmaceuticals sold in Serbia reached US$1.17bn in 2007. Patented products accounted for almost 50% of the market (US$569mn), followed by over-the-counter (OTC) medicines (US$325mn) and generic drugs (US$279mn). Through to 2012, we are forecasting a compound...

  • NHS pays too much for branded drugs. Mayor, Susan // BMJ: British Medical Journal (International Edition);2/24/2007, Vol. 334 Issue 7590, p383 

    The article presents the results of a British government report. The report, which was from the Office of Fair Trading, a body that protects consumers' interests in the United Kingdom, found that health services in the United Kingdom are overpaying approximately $980 million a year for...

  • Drug-price escalation is likely to slow. Toth, David // Fairfield County Business Journal;4/25/2005, Vol. 44 Issue 17, p25 

    The article reports that the Center for Medicare and Medicaid Services (CMS) has stated in a study that although prescription drug spending is at an all-time high, the growth may be slowing and that trend is likely to continue. The high cost of using a brand name medication when a generic brand...

  • Generic medicine a 'sweeter' pill to swallow.  // Finance Week;9/14/2001, p44 

    Focuses the use of generic medicines for the reduction of the cost of medical care in South Africa. Impact of the allotted budget of the government on ethical and generic medicine price; Differential spending of the government on ethical and generic medicines; Beneficial influence of generic...

  • Medicare payment rates will drop 4.3% in 2006.  // Urology Times;9/1/2005, Vol. 33 Issue 11, p4 

    Announces the details of the proposed Medicare Physician Fee Schedule by the Centers for Medicare and Medicaid in the U.S. Proposition of a rule that would lower medical care payment rates; Revisions on payment policies under the proposed rule; Percentage of the reduction required by a statutory...

  • To Your Health.  // Grand Rapids Business Journal;2/16/2004, Vol. 22 Issue 7, p46 

    Focuses on the forecasted rise in U.S. healthcare spending as of February 2004. Growth in healthcare costs in 2002; Forecast on spending growth in prescription medications; Prediction on growth in private health insurance premiums.

  • Nothing Sacred. Mulholland, Stephen // Finweek;4/28/2011, p21 

    In this article the author highlights the underlying factors that add to the cost of production and the total cost of a marketable branded drug manufactured by pharmaceutical companies like research and development, shareholders interests in the form of dividends. For an average hypochondriac in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics